Am J Surg Pathol

1. MARTIN D, Thiryayi S, Grondin K, Pakbaz S, et al
   Gynecologic Pathologist Agreement on Presence and Quantification of Lymphovascular Invasion in Low-stage, Low-grade Endometrial Endometrioid Adenocarcinoma.
   Am J Surg Pathol. 2026 May 11. doi: 10.1097/PAS.0000000000002563.
   

   >> Share

   
   

   
   BMC Cancer

2. ABRAHAMSEN O, Schou JHV, Johansen JS, Jensen MB, et al
   Lower blood glucose levels (HbA1c) within the non-diabetic range are associated with improved survival in patients diagnosed with lung, colon and ovarian cancer: an explorative study.
   BMC Cancer. 2026 Jul 11. doi: 10.1186/s12885-026-16460.
   

   >> Share

   
   
3. NGUYEN HT, Vu MD, Nguyen DD, Dinh PN, et al
   Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
   BMC Cancer. 2026;26:858.
   

   >> Share

   
   

   
   BMJ Oncol

4. ZACHOU G, Wu R, Hutchings A, van der Meulen J, et al
   Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: national population-based study of patient risk factors and cancer characteristics using routinely collected data in England.
   BMJ Oncol. 2026;5:e001053.
   

   >> Share

   
   

   
   Br J Cancer

5. TRECOURT A, Valent A, Yaniz-Galende E, Rouleau E, et al
   Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.
   Br J Cancer. 2026 May 5. doi: 10.1038/s41416-026-03440.
   

   >> Share

   
   

   
   Eur J Obstet Gynecol Reprod Biol

6. JANG EB, Kook Y, So KA, Lee SJ, et al
   Predictive value of primary tumour SUV(max) on (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in patients undergoing fertility-sparing treatment for early endometrial cancer.
   Eur J Obstet Gynecol Reprod Biol. 2026;324:115230.
   

   >> Share

   
   

   
   Gynecol Oncol

7. LEITE LF, da Conceicao LD, de Almeida LFC, de Albuquerque LZ, et al
   Ovarian cancer global trends and disparities across 204 countries and territories.
   Gynecol Oncol. 2026;211:208-216.
   

   >> Share

   
   
8. SEGUIN CL, Eckel A, Howard DH, Peters MLB, et al
   Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
   Gynecol Oncol. 2026;211:178-184.
   

   >> Share

   
   
9. ZHAO CL, Wang XP, Wei K, Ge YJ, et al
   Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian Cancer: Expression and clinicopathological correlations.
   Gynecol Oncol. 2026;211:162-170.
   

   >> Share

   
   
10. ZIMMERMAN J, Dadgar N, Krivak TC, Crafton SM, et al
    Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.
    Gynecol Oncol. 2026;211:138-141.
    

    >> Share

    
    
11. HAIGHT PJ, Sakach JC, Chambers LM, Backes FJ, et al
    Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?
    Gynecol Oncol. 2026;211:132-137.
    

    >> Share

    
    
12. KONG TW, Lee J, Kim J, Son JH, et al
    A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3005).
    Gynecol Oncol. 2026;210:148-152.
    

    >> Share

    
    
13. HAZNEDAR T, Durante S, Lazzari R, Corrao G, et al
    Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours.
    Gynecol Oncol. 2026;210:140-147.
    

    >> Share

    
    
14. PANDRAKLAKIS A, Shearer AM, Ellis LB, Oikonomou MD, et al
    Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.
    Gynecol Oncol. 2026;210:95-105.
    

    >> Share

    
    
15. SMICK AH, Zurek N, Taylor-Harding B, Karlan BY, et al
    Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.
    Gynecol Oncol. 2026;210:55-62.
    

    >> Share

    
    
16. LANGSTRAAT CL, Ostby SA, Vu A, Kalogera ES, et al
    Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery.
    Gynecol Oncol. 2026;210:49-54.
    

    >> Share

    
    
17. LLOYD-ELLIS S, Kaur P, Kwon JS, Dawson L, et al
    Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia.
    Gynecol Oncol. 2026;210:41-48.
    

    >> Share

    
    

    
    Int J Gynaecol Obstet

18. SHCHERBATIUK K, Bultmann S, Karn T, Gasimli K, et al
    Diagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non-atypical endometrial hyperplasia: A systematic review and meta-analysis.
    Int J Gynaecol Obstet. 2026 Feb 26. doi: 10.1002/ijgo.70901.
    

    >> Share

    
    

    
    J Clin Oncol

19. LESNOCK JL, Temin S, Bouberhan S, Adams SF, et al
    Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
    J Clin Oncol. 2026 Jul 13:101200JCO2601591. doi: 10.1200/JCO-26-01591.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share